Trial Profile
A Study of 3 Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs RO 4403726 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Feb 2010 New trial record.